Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

BMS-663068 is an oral prodrug of the HIV-1 attachment inhibitor BMS-626529, which prevents viral attachment to host CD4(+) T cells by binding to HIV-1 gp120. To guide dose selection for the phase 3 program, pharmacokinetic/pharmacodynamic modeling was performed using data from two phase 2 studies wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Landry, Ishani, Zhu, Li, Abu Tarif, Malaz, Hruska, Matthew, Sadler, Brian M., Pitsiu, Maria, Joshi, Samit, Hanna, George J., Lataillade, Max, Boulton, David W., Bertz, Richard J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4862460/
https://ncbi.nlm.nih.gov/pubmed/26902761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02503-15
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados